CAMH-2 is under clinical development by Precirix and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase II drugs for Gastroesophageal (GE) Junction Carcinomas have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CAMH-2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CAMH-2 is under development for the treatment of metastatic HER2 positive breast cancer, gastric cancer and gastroesophageal (GE) junction carcinomas. The drug candidate is an antigen-binding fragment derived from camelid heavy-chain-only antibodies targeting human epidermal growth factor receptor 2 (HER2) labeled with radioisotope iodine I131 using the residualizing radio-iodinating reagent N-succinimidyl 4-guanidinomethyl 3-iodobenzoate (SGMIB). Camelid derived probes are used to transport radioisotopes to selected target receptors on the cancer cell surface. The drug candidate is being developed based on sdAbs technology platform administered through intravenous route.
Precirix, formerly Camel-IDS is a biotechnology company that develops radiopharmaceuticals based on linking single domain antibody fragments with radioisotopes to treat cancer. The company’s lead product candidate CAM-H2 is used for the treatment of HER2-positive cancers. Its technology platform is based on recombinant, small antigen-binding fragments derived from Camelidae heavy-chain-only antibodies coupled with radioisotope to kill cancer cells. Its pipeline products provide delivery of therapeutic radiation to cancer cells, while sparing healthy tissues. It works in collaborations with clinical research institutions and organizations. The company is a spin-off from Vrije Universiteit Brussel (VUB). Precirix is headquartered in Brussels, Bruxelles-Capitale, Belgium.
For a complete picture of CAMH-2’s drug-specific PTSR and LoA scores, buy the report here.